Roblon A/S (CPSE:RBLN B) agreed to acquire VAMAFIL, spol. s r.o. for 8 million on November 9, 2021. Roblon has secured 10.85962 in long-term credit facilities to support the acquisition of Vamafil and the Group's growth strategy in general.
The company has annual revenue of between 4.5m and 5m. The completion of the transaction is subject to confirmatory due diligence on a couple of matters, retention of management and other customary closing conditions. The acquisition date is 3 January 2022.